How a New York cancer center pioneered the era of living drugs
In short: Memorial Sloan Kettering Cancer Center has long been a global leader in oncology, evolving from early radiation experiments to the development of modern immunotherapy. By bridging the gap between laboratory research and clinical practice, the institution has fundamentally changed how we treat cancer, including the creation of revolutionary living drugs.
Memorial Sloan Kettering Cancer Center (MSK) holds a storied place in medical history, having been one of the first institutions to receive the Comprehensive Cancer Center designation from the National Cancer Institute in 1971. Its origins trace back to the 1884 founding of the New York Cancer Hospital, which later merged with the Sloan-Kettering Institute for Cancer Research. This integration of patient care, education, and rigorous scientific inquiry has allowed MSK to establish standardized treatment protocols for hundreds of cancer subtypes.
The center is perhaps best known for its role in pioneering transformative therapies. Scientists at MSK developed Ipilimumab, the first FDA-approved checkpoint inhibitor, which functions by releasing the immune system's natural brakes to fight tumors. More recently, the institution led the development of chimeric antigen receptor (CAR) T cells, approved by the FDA in 2017. These so-called living drugs involve genetically engineering a patient's own immune cells to identify and destroy cancer, marking a significant shift in precision medicine.
Beyond clinical breakthroughs, MSK maintains an extensive research infrastructure. Its programs span basic, translational, and clinical research, organized into multidisciplinary disease management teams. The institution also fosters the next generation of scientists through the Gerstner Sloan Kettering Graduate School of Biomedical Sciences, established in 2004. By maintaining a high degree of specialization and a collaborative environment, MSK continues to refine diagnostic and therapeutic strategies for both pediatric and adult cancers.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Memorial Sloan Kettering Cancer Center | Office of Cancer Centers
- Also: Memorial Sloan Kettering Cancer Center (MSK)
- Also: Memorial Sloan Kettering Cancer Center
To cite this card, link to https://intellectplus.co.uk/app/culture-memorial-sloan-kettering-cancer-center.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in US culture · More in Cultures · Latest · A–Z · All topics
